VISUAL III: Adalimumab in Patients with Active Noninfectious Uveitis

Main finding: Patients with active uveitis at baseline who received adalimumab therapy were likely to achieve quiescence, improve visual acuity, and reduce systemic corticosteroid use. Most patients with inactive uveitis at baseline sustained quiescence without a systemic corticosteroid dose increase.

Study characteristics:

• Name: VISUAL III study
• Purpose: To assess the efficacy and safety of adalimumab in active and inactive uveitis
• Type: Clinical trial extension
• Condition: Non-infectious intermediate, posterior, and panuveitic uveitis controlled by corticosteroids.
• Year results published: 2018